Table 1.
Influence of UDCA and CDCA on the pharmacokinetics of nitrendipine in healthy subjects (mean ± s.d., (95% confidence interval for the difference), n = 6).
| Treatment | Cmax (ng ml−1) | tmax (h) | AUC(0,12 h) (ng ml−1 h) | t (h) |
|---|---|---|---|---|
| Control | 10.9 ± 5.8 | 1.7 ± 0.5 | 60 ± 36 | 3.7 ± 0.4 |
| UDCA 50 mg | 5.0 ± 4.7 | 1.2 ± 0.4 | 15 ± 13 | 2.7 ± 1.1 |
| (3.9, 7.8, P = 0.0006) | (−0.1, 1.1, P = 0.0756) | (20, 73, P = 0.0064) | (−0.8, 1.8. P = 0.3801) | |
| CDCA 200 mg | 8.7 ± 6.1 | 1.7 ± 0.5 | 49 ± 34 | 3.2 ± 0.9 |
| (0.4, 3.8, P = 0.0230) | (−0.7, 0.7, P = 1) | (−2, 26, P = 0.0850) | (−1.2, 1.1, P = 0.9178) | |
| CDCA 600 mg | 5.0 ± 3.9 | 1.8 ± 0.8 | 19 ± 19 | 2.9 ± 1.1 |
| (2.6, 9.2, P = 0.0059) | (−1.2, 0.9, P = 0.6952) | (21, 63, P = 0.0038) | (−1, 3, P = 0.8849) |